Head to head
Lorecivivint against UBX0101
Two injected knee osteoarthritis drugs that both missed on pain. Lorecivivint's two published phase 3 pain trials both missed their primary endpoint and it was filed on joint space width instead; UBX0101 matched placebo on pain at every dose in 183 people.
Column A
LorecivivintLorecivivint (SM04690)
An injected Wnt-pathway small molecule for knee osteoarthritis whose two published Phase 3 pain trials both missed their primary endpoint, now filed with the FDA in January 2026 on long-term joint-space-width data instead.
Column B
UBX0101UBX0101, intra-articular MDM2 to p53 interaction inhibitor (Unity Biotechnology)
The first senolytic taken into a randomised phase 2 trial for a symptom endpoint. In 183 people with knee osteoarthritis, pain scores at 12 weeks were the same on every dose of UBX0101 as on placebo, according to the results Unity Biotechnology posted to ClinicalTrials.gov.
Side by side, on the facts we can check
| Attribute | Lorecivivint | UBX0101 |
|---|---|---|
| Category | Healing & Recovery | Longevity |
| FDA status | NDA under FDA review (submitted January 2026) | Not approved. Investigational; the phase 2 osteoarthritis trial completed in 2020 with results posted to ClinicalTrials.gov in December 2021, and the long-term follow-up study was terminated for inability to achieve primary or secondary study objectives. |
| Half-life | One to two intra-articular injections per year | Not reported |
| Molecular weight | 505.5 Da | Not reported |
| Mechanism | Intra-articular CLK/DYRK1A inhibition that modulates Wnt signaling, reducing inflammation and promoting chondrocyte health. | Established in mice and in cells: inhibiting the MDM2 to p53 interaction prevents p53 degradation, and senescent cells, which depend on suppressing p53-driven apoptosis to survive, die selectively. Delivery is by direct injection into the joint, which was intended to confine the effect to the knee. In humans, whether the injection cleared senescent cells from the joint was not established by the trials, which measured pain and function rather than senescent cell burden. |
| Human studies cited | 3 | 4 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Lorecivivint and UBX0101?
Lorecivivint: An injected Wnt-pathway small molecule for knee osteoarthritis whose two published Phase 3 pain trials both missed their primary endpoint, now filed with the FDA in January 2026 on long-term joint-space-width data instead. UBX0101: The first senolytic taken into a randomised phase 2 trial for a symptom endpoint. In 183 people with knee osteoarthritis, pain scores at 12 weeks were the same on every dose of UBX0101 as on placebo, according to the results Unity Biotechnology posted to ClinicalTrials.gov.
Which has stronger research evidence, Lorecivivint or UBX0101?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Lorecivivint profile were human work, against 4 of 6 for UBX0101. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Lorecivivint and UBX0101 FDA-approved?
Lorecivivint: NDA under FDA review (submitted January 2026). UBX0101: Not approved. Investigational; the phase 2 osteoarthritis trial completed in 2020 with results posted to ClinicalTrials.gov in December 2021, and the long-term follow-up study was terminated for inability to achieve primary or secondary study objectives..
Related posts
Blog articles that cover Lorecivivint or UBX0101, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.